Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADLEY M BLOCK

Allopathic & Osteopathic Physicians Family Medicine

NPI
1205819307
CMS profile
191172
Location
OVIEDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$143.76

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $143.76 10

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADLEY M BLOCK

NPI 1205819307 · CMS profile ID 191172

Allopathic & Osteopathic Physicians / Family Medicine

OVIEDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205819307?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADLEY M BLOCK, NPI 1205819307, CMS profile ID 191172. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205819307?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRADLEY M BLOCK, NPI 1205819307, CMS profile ID 191172. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205819307?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRADLEY M BLOCK, NPI 1205819307, CMS profile ID 191172, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1205819307?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $143.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $23.1711/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810628173 CMS
Bayer HealthCare Pharmaceuticals Inc. $18.8410/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789180505 CMS
PFIZER INC. $1.5409/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833440399 CMS
VistaPharm, Inc. $14.9109/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837691619 CMS
Biogen, Inc. $18.8409/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827759347 CMS
Merck Sharp & Dohme Corporation $11.2608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848486803 CMS
JAZZ PHARMACEUTICALS INC. $15.1108/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845598109 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.4906/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763717448 CMS
Janssen Pharmaceuticals, Inc $14.6203/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787987883 CMS
Daiichi Sankyo Inc. $12.9801/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836245757 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $205.15 15
PY2020 $3,246.75 19
PY2021 $143.76 10
PY2022 $189.20 11
PY2023 $1,359.11 9
PY2024 $376.65 20
PY2025 $4,527.48 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $463,347.97 19
PY2024 Recipient $32,803.00 1
PY2024 Principal investigator $565,590.10 69
PY2023 Recipient $285.00 1
PY2023 Principal investigator $529,627.42 655
PY2022 Recipient $610.00 1
PY2022 Principal investigator $122,619.06 206
PY2021 Recipient $396.44 1
PY2021 Principal investigator $386,856.51 126
PY2020 Recipient $2,077.00 3
PY2020 Principal investigator $684,365.10 151
PY2019 Recipient $1,843.74 2
PY2019 Principal investigator $278,906.72 78

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $2,739.00 12/20/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096759756
Principal investigator 1 SANOFI US SERVICES INC. $8,485.20 12/03/2024 Non-covered Recipient Entity
Oviedo Medical Research
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128724240
Principal investigator 1 Novo Nordisk AS $8,117.80 11/20/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096768389
Principal investigator 1 Novo Nordisk AS $6,009.51 10/31/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096722258
Principal investigator 1 SANOFI US SERVICES INC. $9,814.50 10/21/2024 Non-covered Recipient Entity
Oviedo Medical Research
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128724230
Principal investigator 1 SANOFI US SERVICES INC. $6,200.11 10/15/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724216
Principal investigator 1 SANOFI US SERVICES INC. $7,251.99 10/15/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724228
Principal investigator 1 SANOFI US SERVICES INC. $5,050.00 10/02/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724202
Principal investigator 1 SANOFI US SERVICES INC. $881.94 10/02/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724206
Principal investigator 1 SANOFI US SERVICES INC. $4,279.50 10/02/2024 Non-covered Recipient Entity
Oviedo Medical Research
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128724208
Recipient Eli Lilly and Company $32,803.00 09/27/2024 Covered Recipient Physician A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1137346428
Principal investigator 1 Novo Nordisk AS $17,090.53 09/20/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096738913
Principal investigator 1 Novo Nordisk AS $1,774.68 09/20/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096851362
Principal investigator 1 SANOFI US SERVICES INC. $8,650.99 09/16/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724198
Principal investigator 1 SANOFI US SERVICES INC. $9,888.30 08/26/2024 Non-covered Recipient Entity
Oviedo Medical Research
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128724190
Principal investigator 1 Novo Nordisk AS $6,343.46 08/21/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096858215
Principal investigator 1 SANOFI US SERVICES INC. $14,264.79 08/12/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724164
Principal investigator 1 SANOFI US SERVICES INC. $7,263.90 07/29/2024 Non-covered Recipient Entity
Oviedo Medical Research
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128724176
Principal investigator 1 SANOFI US SERVICES INC. $19,600.00 07/29/2024 Non-covered Recipient Entity
Oviedo Medical Research
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128724182
Principal investigator 1 Novo Nordisk AS $135.54 07/25/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096733896
Principal investigator 1 Novo Nordisk AS $135.54 07/25/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096791904
Principal investigator 1 Novo Nordisk AS $135.54 07/25/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096805081
Principal investigator 1 Novo Nordisk AS $135.54 07/25/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096847307
Principal investigator 1 Novo Nordisk AS $12,304.69 07/22/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096834928
Principal investigator 1 SANOFI US SERVICES INC. $17,564.18 07/15/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724146
Principal investigator 1 Novo Nordisk AS $26.68 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096717705
Principal investigator 1 Novo Nordisk AS $51.96 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096725444
Principal investigator 1 Novo Nordisk AS $26.68 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096761458
Principal investigator 1 Novo Nordisk AS $51.96 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096769663
Principal investigator 1 Novo Nordisk AS $26.68 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096775521
Principal investigator 1 Novo Nordisk AS $26.68 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096780128
Principal investigator 1 Novo Nordisk AS $51.96 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096808677
Principal investigator 1 Novo Nordisk AS $51.96 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096839091
Principal investigator 1 Novo Nordisk AS $26.68 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096842955
Principal investigator 1 Novo Nordisk AS $51.96 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096864365
Principal investigator 1 Novo Nordisk AS $51.96 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096865332
Principal investigator 1 Novo Nordisk AS $51.96 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096875364
Principal investigator 1 Novo Nordisk AS $26.68 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096883176
Principal investigator 1 Novo Nordisk AS $26.68 07/10/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096883197
Principal investigator 1 Novo Nordisk AS $6,853.78 06/21/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096800510
Principal investigator 1 Novo Nordisk AS $17,815.44 05/31/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096830012
Principal investigator 1 Novo Nordisk AS $33.35 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096724975
Principal investigator 1 Novo Nordisk AS $33.35 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096730588
Principal investigator 1 Novo Nordisk AS $64.95 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096730942
Principal investigator 1 Novo Nordisk AS $64.95 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096741602
Principal investigator 1 Novo Nordisk AS $33.35 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096757166
Principal investigator 1 Novo Nordisk AS $33.35 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096759231
Principal investigator 1 Novo Nordisk AS $64.95 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096768018
Principal investigator 1 Novo Nordisk AS $33.35 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096782511
Principal investigator 1 Novo Nordisk AS $64.95 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096835415
Principal investigator 1 Novo Nordisk AS $64.95 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096839112
Principal investigator 1 Novo Nordisk AS $33.35 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096853726
Principal investigator 1 Novo Nordisk AS $64.95 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096867106
Principal investigator 1 Novo Nordisk AS $33.35 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096868362
Principal investigator 1 Novo Nordisk AS $64.95 05/13/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096872233
Principal investigator 1 SANOFI US SERVICES INC. $11,454.68 05/06/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724122
Principal investigator 1 Novo Nordisk AS $1,836.36 04/30/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096801577
Principal investigator 1 Novo Nordisk AS $18,730.09 03/27/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096859917
Principal investigator 1 SANOFI US SERVICES INC. $15,183.46 03/25/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724100
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 03/25/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724102
Principal investigator 1 Eli Lilly and Company $693.27 03/18/2024 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1137357247
Principal investigator 1 SANOFI US SERVICES INC. $11,091.70 03/04/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724091
Principal investigator 1 Novo Nordisk AS $9,348.99 02/23/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096751031
Principal investigator 1 SANOFI US SERVICES INC. $3,850.00 02/20/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724087
Principal investigator 1 Eli Lilly and Company $237.50 01/31/2024 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) No dispute reported 06/30/2026 1137357159
Principal investigator 1 SANOFI US SERVICES INC. $15,407.58 01/29/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724075
Principal investigator 1 Novo Nordisk AS $7,465.35 01/24/2024 Non-covered Recipient Entity
OVIEDO MEDICAL RESEARCH, LLC
NN9536-7545 No dispute reported 06/30/2026 1096822986
Principal investigator 1 Eli Lilly and Company $14,118.00 01/12/2024 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) No dispute reported 06/30/2026 1137355842
Principal investigator 1 SANOFI US SERVICES INC. $14,804.09 01/03/2024 Non-covered Recipient Entity
Oviedo Medical Research
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128724071
Principal investigator 1 Eli Lilly and Company $240,044.00 01/02/2024 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1137356712